UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 9,150 Shares of STERIS plc (NYSE:STE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in shares of STERIS plc (NYSE:STE - Free Report) by 1.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 903,603 shares of the medical equipment provider's stock after selling 9,150 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.92% of STERIS worth $219,160,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of STE. Massachusetts Financial Services Co. MA increased its position in shares of STERIS by 13.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider's stock worth $1,414,453,000 after acquiring an additional 778,613 shares in the last quarter. Impax Asset Management Group plc boosted its stake in STERIS by 29.7% during the 2nd quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider's stock valued at $251,663,000 after acquiring an additional 263,383 shares during the last quarter. Principal Financial Group Inc. boosted its stake in STERIS by 9.5% during the 3rd quarter. Principal Financial Group Inc. now owns 1,114,224 shares of the medical equipment provider's stock valued at $270,230,000 after acquiring an additional 96,336 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in STERIS by 12.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 840,194 shares of the medical equipment provider's stock valued at $184,439,000 after acquiring an additional 95,412 shares during the last quarter. Finally, Raymond James & Associates boosted its stake in STERIS by 1.5% during the 3rd quarter. Raymond James & Associates now owns 801,144 shares of the medical equipment provider's stock valued at $194,309,000 after acquiring an additional 12,005 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company's stock.

Insider Buying and Selling

In related news, SVP Cary L. Majors sold 1,682 shares of the business's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the transaction, the senior vice president now owns 11,372 shares of the company's stock, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Michael J. Tokich sold 23,332 shares of the business's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This trade represents a 35.21 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have commented on STE shares. StockNews.com downgraded shares of STERIS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, October 29th. Piper Sandler upgraded shares of STERIS from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Needham & Company LLC reiterated a "hold" rating on shares of STERIS in a research report on Friday, November 8th. Stephens reissued an "overweight" rating and set a $260.00 target price on shares of STERIS in a research note on Thursday, November 7th. Finally, KeyCorp raised their target price on shares of STERIS from $255.00 to $265.00 and gave the company an "overweight" rating in a research note on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $253.00.

STERIS Trading Up 0.7 %

Shares of STERIS stock traded up $1.59 during trading on Friday, hitting $219.06. The stock had a trading volume of 342,972 shares, compared to its average volume of 728,088. The stock has a 50 day simple moving average of $225.01 and a 200 day simple moving average of $228.28. The company has a market capitalization of $21.62 billion, a PE ratio of 50.01 and a beta of 0.85. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. STERIS plc has a 1 year low of $195.47 and a 1 year high of $248.24.

STERIS (NYSE:STE - Get Free Report) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.02. The business had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The firm's quarterly revenue was up 7.3% compared to the same quarter last year. During the same period last year, the firm posted $2.03 earnings per share. On average, research analysts expect that STERIS plc will post 9.15 EPS for the current fiscal year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Investors of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.04%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS's dividend payout ratio is currently 52.05%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.